A Subject-, Investigator-, and Sponsor-blinded, Randomized, Placebo-controlled, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

Trial Profile

A Subject-, Investigator-, and Sponsor-blinded, Randomized, Placebo-controlled, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs VAY 736 (Primary)
  • Indications Multiple sclerosis; Pemphigus vulgaris; Rheumatoid arthritis; Sjogren's syndrome
  • Focus Pharmacodynamics
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 25 Mar 2018 Planned End Date changed from 29 Jul 2022 to 6 Apr 2022.
    • 25 Mar 2018 Planned primary completion date changed from 29 Jul 2022 to 6 Apr 2022.
    • 25 Mar 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top